Most Widely Prescribed Blood Pressure Medicines Might Not Be Best Option: Study

Kids Trampoline Injuries Take Another Bounce Upwards

Kids Trampoline Injuries Take Another Bounce Upwards FRIDAY, Oct. 25, 2019 -- Trampolines arent just for backyards anymore, and the rise in commercial trampoline parks may be sparking a rise in kids injuries, a new report finds. "While trampolines are

FDA Approves Biorphen FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia

FDA Approves Biorphen FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia DEER PARK, Ill., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical

Questions and Answers: NDMA Impurities in Ranitidine (Commonly Known as Zantac)

Questions and Answers: NDMA Impurities in Ranitidine (Commonly Known as Zantac) October 11, 2019 What patients should know about NDMA impurities in ranitidine Not all ranitidine medicines marketed in the U.S. are being recalled. FDA does not have

FDA Approves Scenesse FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria

FDA Approves Scenesse FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria October 08, 2019 -- The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD) EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizum